Role of predictable biomarkers in early detection of cardiovascular events in Chronic Kidney Disease III and IV

1. Abraham G, Moorthy AV, Aggarwal V. Chronic Kidney Disease: a silent epidemic in Indian subcontinent-strategies for management. J Ind Med Assoc. 2006;104(12):689-91. Search in Google Scholar

2. Muntner P, Jiang He, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death from cardiovascular disease. J Am Soc Nephrolgy. 2002;13:745-53.10.1681/ASN.V13374511856780 Search in Google Scholar

3. Kuhn A, van der Giet M, Kuhlmann MK, Mielke N, Ebert N, Schaeffner ES, et al. Kidney function as risk factor and predictor of cardiovascular outcomes and mortality among older adults. Am J Kidney Dis. 2021;77(3):386-96.10.1053/j.ajkd.2020.09.01533197533 Search in Google Scholar

4. Fu EL, Franko MA, Obergfell A, Dekker FW, Gabrielsen A, Jernberg T, Carrero JJ. High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients. Am Heart J. 2019;216:20-9.10.1016/j.ahj.2019.06.01931382219 Search in Google Scholar

5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.10.1056/NEJMoa04103115385656 Search in Google Scholar

6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266. Search in Google Scholar

7. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. K/DOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-35.10.1053/j.ajkd.2014.01.41624647050 Search in Google Scholar

8. Roberts WL. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation – performance and standardization: a background paper. Circulation. 2004;110(25):572-6.10.1161/01.CIR.0000148986.52696.0715611384 Search in Google Scholar

9. Fraser SD, Roderick PJ, Aitken G, Roth M, Mindell JS, Moon G, et al. Chronic kidney disease, albuminuria and socioeconomic status in the Health Surveys for England 2009 and 2010. J Public Health (Oxf.) 2014;36(4):577-86.10.1093/pubmed/fdt117 Search in Google Scholar

10. Tonelli M, Wiebe N, Guthrie B, James MT, Quan H, Fortin M, et al. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int. 2015;88(4):859-66.10.1038/ki.2015.22826221754 Search in Google Scholar

11. Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic Kidney Disease. Circulation. 2021;143(11):1157-72.10.1161/CIRCULATIONAHA.120.050686796916933720773 Search in Google Scholar

12. Balagopal PB, De Ferranti SD, Cook S, Daniels SR, Gidding SS, Hayman LL, et al. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. Circulation. 2011;123:2749-69.10.1161/CIR.0b013e31821c7c6421555711 Search in Google Scholar

13. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69:89-95.10.1067/mcp.2001.11398911240971 Search in Google Scholar

14. Manolio T. Novel risk markers and clinical practice. N Engl J Med. 2003;349:1587-9.10.1056/NEJMp038136 Search in Google Scholar

15. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2009;53:596-605.10.1053/j.ajkd.2008.10.044 Search in Google Scholar

16. Erlinger TP, Tarver-Carr ME, Powe NR, Appel LJ, Coresh J, Eberhardt MS. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis. 2003; 42:256-63.10.1016/S0272-6386(03)00650-4 Search in Google Scholar

17. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004;15:3184-91.10.1097/01.ASN.0000146422.45434.35 Search in Google Scholar

18. Langston RD, Presley R, Flanders WD, McClellan WM. Renal insufficiency and anaemia are independent risk factors for death among patients with acute myocardial infarction. Kidney Int. 2003;64:1398-405.10.1046/j.1523-1755.2003.00200.x Search in Google Scholar

19. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92:509-14.10.1016/S0002-9149(03)00716-1 Search in Google Scholar

20. Matthew J. Tunbridge, Alan G. Jardine. Atherosclerotic Vascular Disease associated with chronic kidney disease. Cardiology Clinics. 2021;39(3):403-14.10.1016/j.ccl.2021.04.01134247753 Search in Google Scholar

21. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westenorp IC, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999; 19:1986-91.10.1161/01.ATV.19.8.1986 Search in Google Scholar

22. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006;166: 2073-80.10.1001/archinte.166.19.207317060536 Search in Google Scholar

23. Arici M, Walls J. End stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001;59:407-17.10.1046/j.1523-1755.2001.059002407.x Search in Google Scholar

24. Menon V, Greene T, Wang X, Pereira AA, Marcovina SC, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005; 68:766-72.10.1111/j.1523-1755.2005.00455.x16014054 Search in Google Scholar

25. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-96.10.1016/j.jacc.2008.05.068 Search in Google Scholar

26. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-9.10.1016/S0735-1097(99)00608-7 Search in Google Scholar

27. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemiais a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-93.10.1046/j.1523-1755.2002.00324.x Search in Google Scholar

28. Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;21:120-3.10.1053/j.jrn.2010.10.017 Search in Google Scholar

29. Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. N Engl J Med. 1983;309:288-96.10.1056/NEJM198308043090507 Search in Google Scholar

30. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62:707-14.10.1016/0002-9343(77)90874-9 Search in Google Scholar

31. Rifkind BM, Segal P. Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. JAMA. 1983;250:1869-72.10.1001/jama.1983.03340140039025 Search in Google Scholar

32. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia: Relation to renal function and dialysis. Nephron. 1991;57:401-10.10.1159/000186303 Search in Google Scholar

33. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;38: 705-11.10.1016/S0735-1097(01)01450-4 Search in Google Scholar

34. Modi ZJ, Lu Y, Ji N, et al. Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System. JAMA Cardiol. 2019;4(4): 353-62.10.1001/jamacardio.2019.0375648495130892557 Search in Google Scholar

35. Zoccali C, Mallamaci F, Tripepi G, Kapke A, Selewski DT, Dietrich X, et al. Fibrinogen, mortality and incident cardiovascular complications in endstagerenal failure. J Intern Med. 2003;254(2): 132-9.10.1046/j.1365-2796.2003.01180.x12859694 Search in Google Scholar

36. Undas A, Nycz K, Pastuszczak M, Stompor T, Zmudka K. The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. Blood Coagul Fibrinolysis. 2010;21(6):522-7.10.1097/MBC.0b013e32833a903520479639 Search in Google Scholar

37. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2567-73.10.1161/01.ATV.0000241589.52950.4c16917107 Search in Google Scholar

38. Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol. 2017;16:34.10.1186/s12933-017-0515-9534523728279217 Search in Google Scholar

39. Parastatidis I, Thomson L, Burke A, Chenysh J, Nagaswami C, Visser J, et al. Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J Biol Chem. 2008;283(49):33846-53.10.1074/jbc.M805522200259068518818200 Search in Google Scholar

40. Lee SJ, Hong JM, Lee, SE, Kang DR, Ovbiagele B, Dermchuk AM, et al. Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes. BMC Neurol. 2017;17:101.10.1186/s12883-017-0865-7543852928525972 Search in Google Scholar